Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl) cyclopropane acetic acid having characteristic X-ray powder diffraction peaks, designated by 2θ and expressed in degrees, at 6.5±0.2°, 10.0±0.2°, 15.5±0.2°, 18.3±0.2°, 20.4±0.2° and 24.6±0.2°.

2. (Original) The crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 1, characterized by a monoclinic space group *P* 2, and by displaying unit cell parameters comprising: crystal axis lengths of a = 7.95±0.02 Å, *b* = 21.94±0.02 Å, *c* = 17.95±0.02 Å and an angle between the crystal axes of β = 100.03±0.02°.

3. (Amended) The crystalline 1-(((1(*R*)-(3 -(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid according to claim 1 ~~or 2~~, characterized in that it is provided with a purity of greater than 90.0%, preferably greater than 95%, preferably greater than 99%, preferably greater than ~~99, 9~~ 99.9%.

4. (Amended) A process for preparing the crystalline 1-((((l(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to ~~any one of claims 1 to 3~~ claim 1, comprising the steps

- dissolving a salt of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid in a solution A comprising at least one organic solvent,

-converting the salt of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid into acid,

- crystallizing the 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio) methyl)cyclopropane acetic acid, and

- optionally isolating the crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid.

5. (Original) The process according to claim 4, characterized in that the converting step is carried out with a solution B comprising at least one aqueous solution and a chromatographic column, respectively.

6. (Original) The process according to claim 5, characterized in that the dissolving step and converting step are carried out together in a mixture comprising solution A and solution B, preferably in a ratio solution B : solution A of 1:10 to 10:1.

7. (Original) A process according to claim 5, characterized in that the 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid is eluted from the column with the solution A comprising at least one organic solvent.

8. (Original) Amorphous form I of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid having a characteristic DSC thermogram with two endothermic peaks, one at between 43°C and 53°C, preferably between 47°C and 49°C, preferably at 48°C and one at between 143°C and 153°C, preferably between 147°C and 149°C, preferably at 148°C and further having one exothermic peak at between 86°C and 96°C, preferably between 90°C and 92°C, preferably at 91°C.

9. (Original) A process for preparing the amorphous form I of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 8, comprising

grinding the crystal form of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid.

10. (Original) Amorphous form II of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid having a characteristic DSC thermogram as shown in Fig. 9.

11. (Original) The process for preparing the amorphous form II of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid according to claim 10, comprising

- providing a suspension of the crystal form of 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl) propyl)thio)methyl)cyclopropane acetic acid, or a salt thereof, in an acidic aqueous solution and
-isolating said amorphous form II.

12. (Amended) A pharmaceutical composition comprising the crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic acid according to ~~any one of claims 1 to 3, the amorphous form I according to claim 8, and/or the amorphous form II according to claim 10~~ claim 1, and one or more pharmaceutically acceptable carriers or excipients

13. (Amended) Crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl) cyclopropane acetic acid according to ~~any one of claims 1 to 3, the amorphous form I according to claim 8, and/or the amorphous form II according to claim 10~~ claim 1, for the use of treating asthma in a human.

14. (New) A pharmaceutical composition comprising the crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic acid according to the amorphous form I of claim 8, and one or more pharmaceutically acceptable carriers or excipients.

15. (New) A pharmaceutical composition comprising the crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio) methyl) cyclopropane acetic acid according to the amorphous form II of claim 10, and one or more pharmaceutically acceptable carriers or excipients.

16. (New) Crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)- phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl) cyclopropane acetic acid according the amorphous form I of claim 8, for the use of treating asthma in a human.

17. (New) Crystalline 1-(((1(*R*)-(3-(2-(7-chloro-2-quinolinyl)ethenyl)- phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl) cyclopropane acetic acid according to the amorphous form II of claim 10, for the use of treating asthma in a human.